Abstract: Recent advances in the understanding of macrophage biology has revealed that tumor-associated macrophages are very heterogeneous and that several distinct subsets coexist in the tumor microenvironment. These subsets differ not only in terms of expression profile and origin but also in their pro- or anti-tumoral function. Here, the inventors describe a macrophage subset in mouse models of metastatic melanoma that express CD 163. Specific depletion of the CD 163 expressing cells in an anti-PD-1 checkpoint inhibitor resistant melanoma model using cytotoxic lipid nanoparticles conjugated to ?CD163 mAh results in a massive infiltration of CD4+ and activated CD8+ T-cells. Moreover the inventors show that tumors quickly relapsed with combined treatment with anti-PDI antibodies.

Abstract: The present invention relates to agents comprising a binding moiety with binding specificity for SRCR domain 1 of the CD163 receptor, for use in medicine. The invention also relates to methods, uses, kits and compositions comprising such agents.

Abstract: The present invention relates to therapeutic agents for the targeted delivery of an immunosuppressive agent to monocytes and/or monocyte-derived cells comprising a binding moiety with specificity for monocytes and/or monocyte-derived cells and an immunosuppressive agent. In one embodiment, the agent is a glucocorticoid-antibody conjugate. The invention also relates to methods, uses, kits and compositions comprising such agents.

Abstract: The present invention relates to agents comprising a binding moiety with binding specificity for SRCR domain 1 of the CD163 receptor, for use in medicine. The invention also relates to methods, uses, kits and compositions comprising such agents.